Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Troubled REIT ARE shows massive upside potential with strong fundamentals and returns. Click for more on ARE stock and why it ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Even though RGTI stock has already seen an impressive 1,300% increase over the past twelve months, the question persists: ...

Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

While Moderna isn’t looking to replace classical computing with quantum entirely, the company is interested in building a “quantum-enabled biotechnology pipeline.” In conjunction with IBM, the ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Moderna said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the ...

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion ...